Amgen, Astellas deal

The companies formed a JV, Amgen Astellas BioPharma KK (Tokyo, Japan), to co-develop and co-commercialize five Amgen compounds in Japan. The JV will be responsible for the development and commercialization of the compounds in Japan. Amgen will be eligible for undisclosed royalties, and Amgen and Astellas will split 50/50 any remaining profits and costs. Amgen will own 51% of the JV, and Astellas 49%. The partners said the JV, which will comprise both Amgen and Astellas employees and is expected to become operational in Tokyo in October, will become a wholly owned Amgen affiliate "as soon as" 2020. ...